STOCK TITAN

[144] Arteris, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Arteris, Inc. filing a Form 144 notifies a proposed sale of 6,421 common shares (acquired as restricted stock units) with an aggregate market value of $87,197.18, through Morgan Stanley Smith Barney LLC on or about 10/07/2025. The RSUs were recorded as acquired on 10/01/2025 and the filing lists previous sales by the same person totaling 30,538 shares during the prior three months, generating gross proceeds of $336,546.61. The filer affirms no undisclosed material adverse information and references Rule 10b5-1 sales plans used for several prior transactions.

Arteris, Inc. presenta un Form 144 che segnala una vendita proposta di 6,421 azioni ordinarie (acquisite come unità di azioni ristritte) con un valore di mercato aggregato di $87,197.18, tramite Morgan Stanley Smith Barney LLC indicativamente il 10/07/2025. Le RSU sono state registrate come acquisite il 10/01/2025 e la dichiarazione riporta vendite precedenti da parte della stessa persona per un totale di 30,538 azioni nei tre mesi precedenti, generando proventi lordi di $336,546.61. Il dichiarante attesta l’assenza di informazioni materiali avverse non divulgate e fa riferimento a piani di vendita secondo la regola 10b5-1 utilizzati per diverse transazioni precedenti.

Arteris, Inc. presenta un Form 144 que notifica una venta propuesta de 6,421 acciones comunes (adquiridas como unidades de acciones restringidas) con un valor de mercado agregado de $87,197.18, a través de Morgan Stanley Smith Barney LLC alrededor del 10/07/2025. Las RSU se registraron como adquiridas el 10/01/2025 y la presentación indica ventas previas por la misma persona por un total de 30,538 acciones durante los tres meses anteriores, generando ingresos brutos de $336,546.61. El presentante afirma no tener información adversa material no divulgada y hace referencia a planes de venta Rule 10b5-1 usados en varias transacciones anteriores.

Arteris, Inc.Form 144를 제출하여 6,421 주의 보통주를 제약 주식 유닛으로 취득한 상태에서 매각할 예정임을 Morgan Stanley Smith Barney LLC를 통해 10/07/2025 경에 통지합니다. RSU는 10/01/2025에 취득으로 기록되었고, 제출서는 같은 사람의 지난 3개월 동안의 이전 매각이 총 30,538주이며 총 매출액이 $336,546.61의 매출 수익을 생성했다고 기재합니다. 제출자는 비공개의 중요 악재 정보가 없다고 확인하고, 이전 거래들에 사용된 Rule 10b5-1 매매계획을 언급합니다.

Arteris, Inc. dépose un Form 144 qui notifie une vente proposée de 6 421 actions ordinaires (acquises sous forme d’unités d’actions restreintes) d’une valeur marchande totale de $87 197,18, via Morgan Stanley Smith Barney LLC vers le 10/07/2025. Les RSU ont été enregistrées comme acquises le 10/01/2025 et le dépôt indique des ventes antérieures par la même personne totalisant 30 538 actions au cours des trois derniers mois, générant des produits bruts de $336 546,61. Le déclarant affirme qu’il n’existe aucune information matérielle défavorable non divulguée et fait référence à des plans de vente Rule 10b5-1 utilisés pour plusieurs transactions antérieures.

Arteris, Inc. meldet im Formular 144, dass ein geplanter Verkauf von 6.421 Stammaktien (erworben als Restricted Stock Units) mit einem aggregierten Marktwert von $87.197,18 über Morgan Stanley Smith Barney LLC ungefähr am 10/07/2025 vorgesehen ist. Die RSUs wurden am 10/01/2025 als Erwerb verzeichnet, und das Filing listet frühere Verkäufe derselben Person, insgesamt 30.538 Aktien in den vorangegangenen drei Monaten, mit Bruttoerlösen von $336.546,61. Der Einreicher bestätigt, dass es keine unoffenbarten wesentlichen nachteiligen Informationen gibt und verweist auf Verkaufspläne nach Rule 10b5-1, die bei mehreren früheren Transaktionen verwendet wurden.

Arteris, Inc. تقدم Form 144 يخطِر ببيع مقترح لـ 6,421 من أسهم عادية (تم الحصول عليها كصلات أسهم مقيدة) بقيمة سوقية كلية قدرها $87,197.18، من خلال Morgan Stanley Smith Barney LLC في ما يقرب من 10/07/2025. وقد تم تسجيل RSU على أنها مكتسبة في 10/01/2025 وتدرج البلاغة مبيعات سابقة من نفس الشخص بإجمالي 30,538 سهم خلال الأشهر الثلاثة السابقة، محققاً عائدات إجمالية قدرها $336,546.61. يؤكد المصرح عدم وجود معلومات سلبية جوهرية غير مكشوفة ويشير إلى خطط بيع بموجب القاعدة 10b5-1 مستخدمة في عدة معاملات سابقة.

Arteris, Inc. 提交 Form 144,通知拟议出售 6,421 股普通股(以受限股票单位形式取得),总市值为 $87,197.18,通过 Morgan Stanley Smith Barney LLC 于大约 10/07/2025 完成。RSU 已于 10/01/2025 记为取得,申报中还列出同一人过去三个月内的先前出售总计 30,538 股,毛收入为 $336,546.61。申报人声明不存在未披露的重大不利信息,并提及用于若干先前交易的 Rule 10b5-1 交易计划。

Positive
  • Transaction transparency: Filing discloses the proposed sale amount and broker (Morgan Stanley Smith Barney LLC)
  • Source of shares clear: Shares to be sold were acquired as Restricted Stock Units on 10/01/2025
Negative
  • Significant insider selling: 30,538 shares sold in prior three months for gross proceeds of $336,546.61
  • Additional near-term sale: Proposed sale of 6,421 shares on or about 10/07/2025, increasing insider supply

Insights

TL;DR: Insider proposes sale of RSUs and has executed material sales recently.

The filing shows a proposed sale of 6,421 shares acquired as restricted stock units on 10/01/2025

Prior sales by the same person total 30,538 shares for gross proceeds of $336,546.61 over the past three months, with multiple trades executed under 10b5-1 plans. The immediate dependency is the timing noted as "approximate date of sale" 10/07/2025, and execution will occur via Morgan Stanley Smith Barney LLC.

Watch for the actual execution on 10/07/2025 and any subsequent amendment disclosing a different sale amount or cancellation; continued selling at this scale relative to outstanding shares could be meaningful to supply, though no financial performance metrics are provided here.

Arteris, Inc. presenta un Form 144 che segnala una vendita proposta di 6,421 azioni ordinarie (acquisite come unità di azioni ristritte) con un valore di mercato aggregato di $87,197.18, tramite Morgan Stanley Smith Barney LLC indicativamente il 10/07/2025. Le RSU sono state registrate come acquisite il 10/01/2025 e la dichiarazione riporta vendite precedenti da parte della stessa persona per un totale di 30,538 azioni nei tre mesi precedenti, generando proventi lordi di $336,546.61. Il dichiarante attesta l’assenza di informazioni materiali avverse non divulgate e fa riferimento a piani di vendita secondo la regola 10b5-1 utilizzati per diverse transazioni precedenti.

Arteris, Inc. presenta un Form 144 que notifica una venta propuesta de 6,421 acciones comunes (adquiridas como unidades de acciones restringidas) con un valor de mercado agregado de $87,197.18, a través de Morgan Stanley Smith Barney LLC alrededor del 10/07/2025. Las RSU se registraron como adquiridas el 10/01/2025 y la presentación indica ventas previas por la misma persona por un total de 30,538 acciones durante los tres meses anteriores, generando ingresos brutos de $336,546.61. El presentante afirma no tener información adversa material no divulgada y hace referencia a planes de venta Rule 10b5-1 usados en varias transacciones anteriores.

Arteris, Inc.Form 144를 제출하여 6,421 주의 보통주를 제약 주식 유닛으로 취득한 상태에서 매각할 예정임을 Morgan Stanley Smith Barney LLC를 통해 10/07/2025 경에 통지합니다. RSU는 10/01/2025에 취득으로 기록되었고, 제출서는 같은 사람의 지난 3개월 동안의 이전 매각이 총 30,538주이며 총 매출액이 $336,546.61의 매출 수익을 생성했다고 기재합니다. 제출자는 비공개의 중요 악재 정보가 없다고 확인하고, 이전 거래들에 사용된 Rule 10b5-1 매매계획을 언급합니다.

Arteris, Inc. dépose un Form 144 qui notifie une vente proposée de 6 421 actions ordinaires (acquises sous forme d’unités d’actions restreintes) d’une valeur marchande totale de $87 197,18, via Morgan Stanley Smith Barney LLC vers le 10/07/2025. Les RSU ont été enregistrées comme acquises le 10/01/2025 et le dépôt indique des ventes antérieures par la même personne totalisant 30 538 actions au cours des trois derniers mois, générant des produits bruts de $336 546,61. Le déclarant affirme qu’il n’existe aucune information matérielle défavorable non divulguée et fait référence à des plans de vente Rule 10b5-1 utilisés pour plusieurs transactions antérieures.

Arteris, Inc. meldet im Formular 144, dass ein geplanter Verkauf von 6.421 Stammaktien (erworben als Restricted Stock Units) mit einem aggregierten Marktwert von $87.197,18 über Morgan Stanley Smith Barney LLC ungefähr am 10/07/2025 vorgesehen ist. Die RSUs wurden am 10/01/2025 als Erwerb verzeichnet, und das Filing listet frühere Verkäufe derselben Person, insgesamt 30.538 Aktien in den vorangegangenen drei Monaten, mit Bruttoerlösen von $336.546,61. Der Einreicher bestätigt, dass es keine unoffenbarten wesentlichen nachteiligen Informationen gibt und verweist auf Verkaufspläne nach Rule 10b5-1, die bei mehreren früheren Transaktionen verwendet wurden.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Arteris (AIP) Form 144 report?

The Form 144 reports a proposed sale of 6,421 common shares (RSUs) valued at $87,197.18, with an approximate sale date of 10/07/2025.

Who will execute the sale on Form 144 for AIP?

The filing lists Morgan Stanley Smith Barney LLC as the broker handling the proposed sale.

Were there recent insider sales by the same person at Arteris (AIP)?

Yes. The filing shows the person sold a total of 30,538 shares in the prior three months, receiving gross proceeds of $336,546.61.

What is the acquisition method for the shares being sold?

The shares were acquired as Restricted Stock Units on 10/01/2025.

Does the filer assert any undisclosed material information?

By signing, the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.
Arteris, Inc.

NASDAQ:AIP

AIP Rankings

AIP Latest News

AIP Latest SEC Filings

AIP Stock Data

579.19M
29.79M
30.11%
47.91%
3.85%
Semiconductors
Semiconductors & Related Devices
Link
United States
CAMPBELL